PMID- 33120908
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201128
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 12
IP  - 11
DP  - 2020 Oct 27
TI  - Primary Granulocyte Colony-Stimulating Factor Prophylaxis in Metastatic 
      Pancreatic Cancer Patients Treated with FOLFIRINOX as the First-Line Treatment.
LID - 10.3390/cancers12113137 [doi]
LID - 3137
AB  - Although FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) has 
      been proven efficacious in metastatic pancreatic cancer (MPC), physicians 
      hesitate to administer it due to its hematologic toxicities. We investigated the 
      usefulness of primary granulocyte colony-stimulating factor (G-CSF) prophylaxis. 
      We reviewed electronic medical records of MPC patients with good performance 
      status who were administered FOLFIRINOX as the first-line treatment from 2011 to 
      2017. The patients were divided into primary G-CSF prophylaxis users (group A) 
      and non-users or therapeutic/secondary users (group B). Cumulative relative dose 
      (cRDI), adverse effects (AEs), and overall survival (OS) were compared. A total 
      of 165 patients (group A (57) vs. group B (108)) were investigated. Intergroup 
      differences in baseline characteristics were not significant, although the cRDI 
      and the number of treatment cycles were both higher in group A than in group B 
      (cRDI: 80.6% vs. 73.9%, p = 0.007; 9 vs. 6 cycles, p = 0.004). Primary G-CSF 
      prophylaxis reduced the risk of neutropenia (55.6% to 31.6%, p = 0.003) and 
      febrile neutropenia (18.5% to 1.8%, p = 0.002) and improved OS (8.8 to 14.7 
      months; hazard ratio [HR]: 1.766, 95% CI: 1.257-2.481, p = 0.001). When 
      administering FOLFIRINOX for MPC, primary G-CSF prophylaxis could be rationalized 
      to reduced AEs and improve survival; more prospective studies are needed.
FAU - Jung, Jae Hyup
AU  - Jung JH
AD  - Department of Internal Medicine, Seoul National University College of Medicine, 
      Seoul National University Bundang Hospital, Seongnam 13620, Korea.
FAU - Shin, Dong Woo
AU  - Shin DW
AD  - Division of Gastroenterology, Department of Internal Medicine, Keimyung 
      University School of Medicine, Keimyung University Dongsan Medical Center, Daegu 
      42601, Korea.
FAU - Kim, Jaihwan
AU  - Kim J
AD  - Department of Internal Medicine, Seoul National University College of Medicine, 
      Seoul National University Bundang Hospital, Seongnam 13620, Korea.
FAU - Lee, Jong-Chan
AU  - Lee JC
AD  - Department of Internal Medicine, Seoul National University College of Medicine, 
      Seoul National University Bundang Hospital, Seongnam 13620, Korea.
AD  - Division of Gastroenterology, Department of Internal Medicine, Seoul National 
      University Bundang Hospital 82, Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam-si, 
      Gyeonggi-do, Seongnam 13620, Korea.
FAU - Hwang, Jin-Hyeok
AU  - Hwang JH
AD  - Department of Internal Medicine, Seoul National University College of Medicine, 
      Seoul National University Bundang Hospital, Seongnam 13620, Korea.
AD  - Division of Gastroenterology, Department of Internal Medicine, Seoul National 
      University Bundang Hospital 82, Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam-si, 
      Gyeonggi-do, Seongnam 13620, Korea.
LA  - eng
PT  - Journal Article
DEP - 20201027
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC7692712
OTO - NOTNLM
OT  - FOLFIRINOX
OT  - G-CSF prophylaxis
OT  - pancreatic cancer
COIS- The authors declare no conflict of interest.
EDAT- 2020/10/31 06:00
MHDA- 2020/10/31 06:01
PMCR- 2020/10/27
CRDT- 2020/10/30 01:01
PHST- 2020/09/25 00:00 [received]
PHST- 2020/10/22 00:00 [revised]
PHST- 2020/10/24 00:00 [accepted]
PHST- 2020/10/30 01:01 [entrez]
PHST- 2020/10/31 06:00 [pubmed]
PHST- 2020/10/31 06:01 [medline]
PHST- 2020/10/27 00:00 [pmc-release]
AID - cancers12113137 [pii]
AID - cancers-12-03137 [pii]
AID - 10.3390/cancers12113137 [doi]
PST - epublish
SO  - Cancers (Basel). 2020 Oct 27;12(11):3137. doi: 10.3390/cancers12113137.